FitLife Brands, Inc. (FTLF) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. Positive aspects include potential revenue synergies from the FitLife-Irwin merger and the likelihood of inclusion in the Russell 2000 Index. However, the lack of forward-looking guidance and challenges with Dr. Tobias brand balance these positives. The Q&A section reinforces this neutral stance with uncertainties regarding Irwin's revenue growth and the integration process. Overall, the absence of clear guidance and the focus on addressing brand challenges suggest a cautious market reaction, resulting in a neutral stock price prediction.
Key Financial Performance
Total Revenue Declined 5% year-over-year to $16.1 million. The decline is attributed to overall market conditions.
Online Sales $10.4 million or 65% of total revenue. No year-over-year change mentioned.
Gross Profit Declined 9%. Gross margin declined from 44.8% to 42.8% year-over-year. The decline is due to increased costs and market conditions.
Net Income $1.7 million compared to $2.6 million in the previous year, a decline attributed to elevated merger and acquisition-related expenses.
Basic Earnings Per Share Declined from $0.29 to $0.19 year-over-year.
Diluted Earnings Per Share Declined from $0.27 to $0.18 year-over-year.
Adjusted EBITDA $3.3 million, a 13% decrease year-over-year, bringing the trailing 12 months to $13.4 million.
Net Debt $4.3 million, equivalent to approximately 0.3x the company's adjusted EBITDA.
Legacy FitLife Revenue $7.3 million, a 7% increase year-over-year. Wholesale revenue increased 1%, and online revenue increased 17%.
Legacy FitLife Gross Margin Increased to 43.8% compared to 44.2% in the previous year.
MRC Revenue $6.3 million, down 16% year-over-year. Decline attributed to tariffs and product mix issues.
MRC Gross Margin Declined to 46.5% from 48.2% year-over-year. Tariffs and product mix were the primary reasons for the decline.
MusclePharm Revenue Declined 4% year-over-year. Wholesale revenue declined 6%, and online revenue declined 3%.
MusclePharm Gross Margin Declined from 36.6% to 30.8% year-over-year. Decline attributed to targeted investments in advertising and promotion.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MusclePharm Pro Series: Launched in mid-March 2025 as a collection of premium sports nutrition products. Initially piloted in high-volume Vitamin Shoppe stores and later expanded to online and international wholesale partners.
Irwin Naturals Acquisition: FitLife completed the acquisition of Irwin Naturals and its affiliates on August 8, 2025. Irwin's nutritional supplement business generated approximately $60 million in revenue for the trailing 12 months as of June 30, 2025, with a gross margin of 35%. The acquisition is expected to contribute to combined revenue exceeding $120 million and adjusted EBITDA of $20-$25 million for the first full year of operations.
Revenue Decline: Total revenue declined 5% year-over-year to $16.1 million in Q2 2025. Online sales accounted for 65% of total revenue.
Legacy FitLife Performance: Legacy FitLife revenue increased 7% year-over-year to $7.3 million, driven by a 17% increase in online sales and a 1% increase in wholesale revenue.
MRC Performance: Revenue declined 16% year-over-year to $6.3 million, with gross margin dropping to 46.5% due to tariffs and product mix issues.
MusclePharm Performance: Revenue declined 4% year-over-year, with gross margin falling from 36.6% to 30.8%. Targeted advertising and promotional investments are ongoing to drive growth.
Irwin Naturals Bankruptcy and Strategic Shift: Irwin Naturals faced bankruptcy due to an unsuccessful expansion into ketamine clinics. FitLife acquired the brand, refocusing on its core nutritional supplement business and aiming for operational improvements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total revenue declined 5% year-over-year to $16.1 million, with gross profit and gross margin also decreasing. This indicates potential challenges in maintaining sales growth and profitability.
M&A-Related Expenses: Elevated merger and acquisition-related expenses associated with the acquisition of Irwin Naturals negatively impacted net income, which declined from $2.6 million to $1.7 million year-over-year.
MRC Brand Challenges: MRC revenue declined 16% year-over-year, with gross margin dropping due to tariffs and unfavorable product mix. Contribution also decreased, indicating operational inefficiencies.
Tariffs Impact: A 25% tariff on skincare brands under MRC significantly reduced gross margins, cutting profitability for these products by approximately half.
MusclePharm Revenue Decline: MusclePharm revenue declined 4%, with gross margin dropping from 36.6% to 30.8%. Targeted advertising and promotional investments have yet to yield consistent growth.
Dr. Tobias Brand Traffic Issues: The Dr. Tobias brand is experiencing reduced session counts on Amazon, leading to lower traffic despite stable conversion rates. This poses a challenge in driving online sales growth.
Irwin Naturals Bankruptcy History: Irwin Naturals faced bankruptcy due to failed expansion into ketamine clinics and loss of major customers like Costco U.S., raising concerns about its operational stability and integration risks.
Post-Acquisition Uncertainties: Uncertainties related to the integration of Irwin Naturals and achieving projected revenue and EBITDA targets could impact overall business performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue and Adjusted EBITDA Projections: For the first full year of operations, the combined FitLife and Irwin businesses are expected to generate in excess of $120 million of revenue and adjusted EBITDA of between $20 million to $25 million.
Irwin Naturals Gross Margin Improvement: FitLife expects to improve Irwin Naturals' gross margins over time by increasing the percentage of revenue generated from online sales and focusing on making the supply chain more efficient.
Irwin Naturals SG&A Reduction: Annual SG&A for Irwin Naturals is expected to be approximately $1.5 million lower based on the number of employees rehired by FitLife as part of the transaction, with further cost savings opportunities anticipated.
MusclePharm Revenue Growth Initiatives: The company is making targeted investments in advertising and promotion in both wholesale and online channels to drive revenue growth for the MusclePharm brand. Additional promotional incentives are being offered to certain wholesale partners.
Dr. Tobias Brand Traffic Initiatives: FitLife is focused on increasing session counts for the Dr. Tobias brand through targeted advertising spend, improved SEO, and driving external traffic to Amazon product pages. Year-over-year comparisons are expected to be more favorable later in the year if session counts remain stable.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide commentary on the growth rate for the organic business in the second half of the year?
A:Management is optimistic about achieving organic growth in the legacy business, excluding the Irwin acquisition. They noted a $1.4 million decline in the first half of the year compared to last year, primarily due to challenges with the Dr. Tobias brand. Excluding Dr. Tobias, the rest of the business grew by 4%. They remain hopeful for organic revenue growth in 2025 despite these challenges.
Q:Are we looking at high 30% blended gross margins for the combined FitLife and Irwin businesses?
A:Yes, management estimates high 30% blended gross margins for the combined businesses. They noted that Irwin's gross margin is around 35%, and FitLife's historical margins were in the mid-to-high 30s. They expect margins to increase as more products are sold online. Adjustments were made to normalize accounting practices and exclude Costco-related effects.
Q:Are there any potential revenue synergies between FitLife and Irwin?
A:Yes, management highlighted potential revenue synergies, including internalizing Irwin's online sales (currently handled by third parties) and leveraging Irwin's strong mass-market commercial sales team to expand distribution for FitLife's products, such as MusclePharm, in retailers like CVS, Walmart, and Walgreens.
Q:Can you comment on the seasonality of Irwin's business relative to FitLife's?
A:Irwin's business has a similar seasonal trend to FitLife's but with less pronounced fluctuations. While sports nutrition (FitLife's focus) sees a 20-25% revenue drop in November-December compared to January-February, Irwin's general health products experience only about half that decline.
Q:Do Irwin and FitLife spend a similar percentage of revenue on marketing and advertising?
A:No, Irwin significantly reduced its advertising and marketing during bankruptcy, spending only a few hundred thousand dollars. FitLife plans to reintroduce advertising and marketing for Irwin to drive growth.
Q:Are there any anticipated restructuring costs for Irwin?
A:No, there are no anticipated restructuring costs. The transaction was an asset purchase, and any severance or layoff costs for employees not hired by FitLife are not their responsibility. However, there will be incremental one-time expenses, such as legal, audit, and valuation costs.
Q:Will FitLife file pro forma financials for Irwin?
A:Yes, FitLife is required to file abbreviated financial statements for Irwin within 75 days of closing. These will include revenue, cost of goods, gross profit, and operating expenses for the nutritional supplement business acquired. Pro forma financials will also be abbreviated and exclude non-acquired businesses like cannabis and ketamine clinics.
Q:Why did Costco drop two Irwin product lines?
A:Costco requires significant promotional support, which can impact margins. Irwin, during bankruptcy, may not have been in a position to provide the required support. Management noted that Costco is open to resuming discussions post-bankruptcy, and Irwin's products continue to be sold online and in Costco Canada.
Q:Is Dr. Tobias the only weak brand at Mimi's Rock?
A:Dr. Tobias, which constitutes about 92-93% of Mimi's Rock's revenue, is the primary weak brand. The two skincare brands also face challenges, including tariffs on products sold in Canada. Management is prioritizing addressing issues with Dr. Tobias.
Q:Are there steps to mitigate tariffs on skincare products sold in Canada?
A:Yes, but management considers it a low priority due to the relatively small financial impact (low tens of thousands of dollars). The manufacturer moved operations from Canada to Florida, causing tariff implications. Management is focused on higher-priority issues like Dr. Tobias and the Irwin integration.
Q:What are the biggest opportunities for Irwin's revenue growth?
A:Management sees significant opportunities in taking Irwin's products online, particularly on Amazon, where they currently have no direct sales. They also plan to leverage Irwin's strong retail relationships to expand distribution for FitLife's brands, such as MusclePharm.
Q:Should investors focus on individual brand performance or overall company performance?
A:Management suggests focusing on overall company performance but acknowledges that investors may have concerns about specific brands like Mimi's Rock. Dr. Tobias is a cash cow but currently faces challenges, while the skincare brands are not core to the business.
Q:What is the timeline for future M&A activity?
A:Management is focused on integrating Irwin and addressing challenges with Mimi's Rock. While they are not planning to close another deal in the next quarter, they will continue exploring opportunities to stay in the deal flow for potential transactions in 6-18 months.
Q:Is there a minimum threshold for future acquisitions?
A:Yes, management prefers acquisitions with at least $1.5-$2 million in EBITDA. They are open to both larger transformative deals and smaller tuck-ins, provided the latter offer significant ROI and minimal integration effort.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical guidance on the expected revenue growth for Irwin's online sales and the exact timeline for achieving synergies. They also did not provide detailed pro forma financials for Irwin, citing the unique nature of the transaction and the need to confirm requirements with the SEC.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Hansen
CFO FitLife
Capital LLC
Chairman CEO
Conference Instructions
Contribution Technical
Dayton Judd
Difficulty collection
Difficulty regard
Division Samir
Division Sean
ET day
Executive Vice
FitLife Sir
FitLife year
Hansen Executive
Instructions pleasure
Irwin Naturals
Judd Chairman
LLC Conference
LLC Research
Legacy FitLife
MRC Legacy
Markets LLC
MusclePharm Technical
Naturals affiliate
Naturals transaction
Partners LLC
Patel Askeladden
Patrick
Research Division
Technical Difficulty
effort
tariff skin
FTLF Transcript
FitLife Brands, Inc. (FTLF) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call shows strong revenue growth, driven by the acquisition of Irwin. However, the decline in gross margins and weakness in Legacy FitLife are concerns. The lack of discussion on shareholder returns and unclear management responses in the Q&A section add uncertainty. Overall, the positive revenue growth is offset by these concerns, leading to a neutral sentiment.
FitLife Brands, Inc. (FTLF) Q4 2025 Earnings Call Transcript
Unknown4-2
The earnings call summary focuses on the acquisition of Irwin Naturals, with no mention of financial performance or shareholder returns. The Q&A section lacks substantial insights, and there is no indication of strong positive or negative catalysts. With the absence of market cap information and strategic guidance, the stock reaction is likely neutral, as investors await more clarity on acquisition integration and financial performance.
FitLife Brands, Inc. (FTLF) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals several negative factors: declining margins, increased tax expenses, and unresolved issues with Dr. Tobias on Amazon. Although MusclePharm shows growth, it's primarily from existing customers. Rising protein costs and potential further margin declines are concerning. Despite optimistic guidance for Irwin's online sales, the lack of clarity on subscriber trends and management's avoidance of detailed responses contribute to a negative sentiment. Without a market cap, the negative impact is assumed to be moderate.
FitLife Brands, Inc. (FTLF) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call summary presents a mixed picture. Positive aspects include potential revenue synergies from the FitLife-Irwin merger and the likelihood of inclusion in the Russell 2000 Index. However, the lack of forward-looking guidance and challenges with Dr. Tobias brand balance these positives. The Q&A section reinforces this neutral stance with uncertainties regarding Irwin's revenue growth and the integration process. Overall, the absence of clear guidance and the focus on addressing brand challenges suggest a cautious market reaction, resulting in a neutral stock price prediction.
FTLF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
